NASDAQ:IRMD - IRadimed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.45 -0.10 (-0.54 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$18.45
Today's Range$18.42 - $18.70
52-Week Range$8.00 - $19.25
Volume10,828 shs
Average Volume25,282 shs
Market Capitalization$196.60 million
P/E Ratio230.63
Dividend YieldN/A
Beta1.4

About IRadimed (NASDAQ:IRMD)

IRadimed logoIRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Debt-to-Equity RatioN/A
Current Ratio9.19
Quick Ratio8.10

Price-To-Earnings

Trailing P/E Ratio230.63
Forward P/E Ratio57.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$23.08 million
Price / Sales8.52
Cash Flow$0.2154 per share
Price / Cash85.64
Book Value$3.21 per share
Price / Book5.75

Profitability

EPS (Most Recent Fiscal Year)$0.08
Net Income$490,000.00
Net Margins6.29%
Return on Equity6.27%
Return on Assets5.32%

Miscellaneous

Employees83
Outstanding Shares10,660,000

IRadimed (NASDAQ:IRMD) Frequently Asked Questions

What is IRadimed's stock symbol?

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

How will IRadimed's stock buyback program work?

IRadimed announced that its Board of Directors has approved a stock buyback plan on Sunday, June 4th 2017, which permits the company to repurchase $8,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its shares are undervalued.

How were IRadimed's earnings last quarter?

IRadimed Corp (NASDAQ:IRMD) posted its quarterly earnings results on Monday, April, 30th. The medical equipment provider reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.04. The medical equipment provider earned $7.11 million during the quarter, compared to the consensus estimate of $6.83 million. IRadimed had a return on equity of 6.27% and a net margin of 6.29%. View IRadimed's Earnings History.

When is IRadimed's next earnings date?

IRadimed is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for IRadimed.

What price target have analysts set for IRMD?

2 brokers have issued 12-month price objectives for IRadimed's shares. Their forecasts range from $16.00 to $19.00. On average, they anticipate IRadimed's share price to reach $17.50 in the next year. View Analyst Ratings for IRadimed.

Who are some of IRadimed's key competitors?

Who are IRadimed's key executives?

IRadimed's management team includes the folowing people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 65)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 48)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 59)
  • Mr. John McCreery, Chief Operating Officer (Age 63)
  • Mr. Louis Waldman, Controller (Age 63)

Has IRadimed been receiving favorable news coverage?

Media stories about IRMD stock have trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IRadimed earned a media sentiment score of 0.13 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 43.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are IRadimed's major shareholders?

IRadimed's stock is owned by many different of institutional and retail investors. Top institutional investors include Mondrian Investment Partners LTD (1.86%), Boston Partners (0.70%), Russell Investments Group Ltd. (0.55%), Granite Investment Partners LLC (0.34%), Spark Investment Management LLC (0.29%) and Northern Trust Corp (0.25%). Company insiders that own IRadimed stock include Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for IRadimed.

Which institutional investors are selling IRadimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Mondrian Investment Partners LTD and Spark Investment Management LLC. Company insiders that have sold IRadimed company stock in the last year include Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for IRadimed.

Which institutional investors are buying IRadimed stock?

IRMD stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Russell Investments Group Ltd., O Shaughnessy Asset Management LLC and Northern Trust Corp. View Insider Buying and Selling for IRadimed.

How do I buy shares of IRadimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IRadimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $18.45.

How big of a company is IRadimed?

IRadimed has a market capitalization of $196.60 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. IRadimed employs 83 workers across the globe.

How can I contact IRadimed?

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for IRadimed (IRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about IRadimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IRadimed (NASDAQ:IRMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for IRadimed in the last 12 months. Their average twelve-month price target is $17.50, suggesting that the stock has a possible downside of 5.15%. The high price target for IRMD is $19.00 and the low price target for IRMD is $16.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.50$17.50$17.50$17.50
Price Target Upside: 5.15% downside29.63% upside29.63% upside29.63% upside

IRadimed (NASDAQ:IRMD) Consensus Price Target History

Price Target History for IRadimed (NASDAQ:IRMD)

IRadimed (NASDAQ:IRMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2017Credit Suisse GroupInitiated CoverageBuy$19.00LowView Rating Details
10/31/2017Roth CapitalInitiated CoverageBuy ➝ Buy$16.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

IRadimed (NASDAQ:IRMD) Earnings History and Estimates Chart

Earnings by Quarter for IRadimed (NASDAQ:IRMD)

IRadimed (NASDAQ:IRMD) Earnings Estimates

Current Year EPS Consensus Estimate: $0.32 EPS
Next Year EPS Consensus Estimate: $0.47 EPS

IRadimed (NASDAQ IRMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2018        
4/30/2018Q1 2018$0.06$0.10$6.83 million$7.11 millionViewListenView Earnings Details
2/6/2018Q4 2017$0.02$0.06$6.72 million$6.70 millionViewN/AView Earnings Details
10/30/2017Q3 2017($0.28)$0.07$5.60 million$5.69 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.01)$0.06$5.41 million$5.50 millionViewN/AView Earnings Details
4/28/2017Q1 2017($0.02)($0.02)$5.26 million$5.16 millionViewN/AView Earnings Details
2/6/2017Q416$0.04$0.11$6.09 million$6.00 millionViewListenView Earnings Details
10/28/2016Q316$0.09$0.14$7.50 million$7.70 millionViewListenView Earnings Details
7/29/2016Q216$0.21$0.24$9.60 million$9.90 millionViewListenView Earnings Details
4/29/2016Q1$0.18$0.21$9.05 million$8.96 millionViewListenView Earnings Details
2/5/2016Q415$0.19$0.22$8.80 million$8.80 millionViewN/AView Earnings Details
10/30/2015Q315$0.16$0.19$7.70 million$8.20 millionViewListenView Earnings Details
7/30/2015Q215$0.12$0.15$7.10 million$7.60 millionViewListenView Earnings Details
4/30/2015Q115$0.10$0.12$6.90 million$7.00 millionViewN/AView Earnings Details
2/5/2015Q4($0.01)$0.02$3.50 million$3.58 millionViewN/AView Earnings Details
10/30/2014Q3$0.01$0.02$3.80 million$3.80 millionViewN/AView Earnings Details
8/12/2014Q214$0.11$2.80 million$4.70 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

IRadimed (NASDAQ:IRMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

IRadimed (NASDAQ IRMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 61.20%
Institutional Ownership Percentage: 17.40%
Insider Trading History for IRadimed (NASDAQ:IRMD)
Institutional Ownership by Quarter for IRadimed (NASDAQ:IRMD)

IRadimed (NASDAQ IRMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2018Louis S. WaldmanInsiderSell5,221$18.19$94,969.99View SEC Filing  
5/2/2018Monty K AllenDirectorSell1,899$17.94$34,068.0619,972View SEC Filing  
3/16/2018Louis S WaldmanInsiderSell30,000$13.83$414,900.005,221View SEC Filing  
3/16/2018Roger E SusiCEOBuy1,000$13.85$13,850.0021,000View SEC Filing  
12/4/2017Monty K AllenDirectorSell1,898$13.95$26,477.109,062View SEC Filing  
6/1/2017Steven M NardiVPSell4,634$8.32$38,554.882,194View SEC Filing  
2/9/2017Roger E SusiCEOBuy10,000$8.60$86,000.0015,000View SEC Filing  
11/29/2016Roger E SusiCEOBuy5,000$11.24$56,200.0010,000View SEC Filing  
11/15/2016Roger E SusiCEOBuy5,000$10.46$52,300.005,000View SEC Filing  
8/16/2016Steven M NardiVPSell2,096$17.11$35,862.561,996View SEC Filing  
6/14/2016Monty K. AllenDirectorSell2,275$20.00$45,500.00View SEC Filing  
6/13/2016Monty K AllenDirectorSell2,100$20.44$42,924.004,375View SEC Filing  
2/19/2016Serge NovovichDirectorSell2,910$17.23$50,139.30107,546View SEC Filing  
2/18/2016Steven M NardiVPSell192$17.00$3,264.002,288View SEC Filing  
12/23/2015Roger E SusiCEOSell156,521$23.28$3,643,808.88View SEC Filing  
12/18/2015Roger E SusiCEOSell1,043,479$23.28$24,292,191.12View SEC Filing  
12/16/2015Steven M. NardiVPSell4,438$26.80$118,938.40100View SEC Filing  
12/8/2015Brent JohnsonVPSell22,659$30.92$700,616.28View SEC Filing  
12/7/2015Steven M. NardiVPSell624$31.02$19,356.48600View SEC Filing  
12/4/2015Brent JohnsonVPSell400$31.51$12,604.00View SEC Filing  
12/3/2015Brent JohnsonVPSell26,880$31.52$847,257.60View SEC Filing  
12/1/2015Serge NovovichDirectorSell1,000$31.12$31,120.00100,983View SEC Filing  
11/25/2015James B. HawkinsDirectorSell5,290$30.98$163,884.2083,460View SEC Filing  
8/25/2015Monty K. AllenDirectorSell6,250$24.85$155,312.50View SEC Filing  
12/29/2014Steven M NardiVPBuy2,100$12.58$26,418.00View SEC Filing  
7/21/2014James B HawkinsDirectorBuy80,000$6.25$500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

IRadimed (NASDAQ IRMD) News Headlines

Source:
DateHeadline
Financial Review: Cerus (CERS) & IRadimed (IRMD)Financial Review: Cerus (CERS) & IRadimed (IRMD)
www.americanbankingnews.com - May 25 at 3:18 AM
Zacks: IRadimed Corp (IRMD) Given Average Recommendation of "Strong Buy" by AnalystsZacks: IRadimed Corp (IRMD) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 23 at 9:28 AM
IRadimed Corp (IRMD) Insider Sells $94,969.99 in StockIRadimed Corp (IRMD) Insider Sells $94,969.99 in Stock
www.americanbankingnews.com - May 8 at 8:17 PM
IRadimed (IRMD) Upgraded to Buy by Zacks Investment ResearchIRadimed (IRMD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 5 at 1:51 AM
IRadimed Corp (IRMD) Director Monty K. Allen Sells 1,899 SharesIRadimed Corp (IRMD) Director Monty K. Allen Sells 1,899 Shares
www.americanbankingnews.com - May 4 at 1:22 PM
Zacks: Brokerages Set $21.00 Price Target for IRadimed Corp (IRMD)Zacks: Brokerages Set $21.00 Price Target for IRadimed Corp (IRMD)
www.americanbankingnews.com - May 4 at 11:30 AM
IRadimed (IRMD) Upgraded to "Buy" at ValuEngineIRadimed (IRMD) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - May 4 at 12:19 AM
CORRECTED-BRIEF-IRadimed Corporation Q1 GAAP Earnings Per Share $0.07 (April 30)CORRECTED-BRIEF-IRadimed Corporation Q1 GAAP Earnings Per Share $0.07 (April 30)
www.reuters.com - May 1 at 9:36 AM
Edited Transcript of IRMD earnings conference call or presentation 30-Apr-18 3:00pm GMTEdited Transcript of IRMD earnings conference call or presentation 30-Apr-18 3:00pm GMT
finance.yahoo.com - May 1 at 9:36 AM
IRADIMEDs (IRMD) CEO Roger Susi on Q1 2018 Results - Earnings Call TranscriptIRADIMED's (IRMD) CEO Roger Susi on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 30 at 4:20 PM
BRIEF-IRadimed Reports Q1 Non-GAAP EPS Of $0.10BRIEF-IRadimed Reports Q1 Non-GAAP EPS Of $0.10
www.reuters.com - April 30 at 4:20 PM
IRadimed (IRMD) Posts Quarterly  Earnings ResultsIRadimed (IRMD) Posts Quarterly Earnings Results
www.americanbankingnews.com - April 30 at 11:16 AM
BRIEF-IRadimed Corporation Q1 GAAP Earnings Per Share $0.07BRIEF-IRadimed Corporation Q1 GAAP Earnings Per Share $0.07
www.reuters.com - April 30 at 9:47 AM
iRadimed Q1 revenues up 37%; raises fiscal guidanceiRadimed Q1 revenues up 37%; raises fiscal guidance
seekingalpha.com - April 30 at 9:47 AM
IRadimed: 1Q Earnings SnapshotIRadimed: 1Q Earnings Snapshot
www.cnbc.com - April 30 at 9:47 AM
IRADIMED CORPORATION Announces First Quarter 2018 Financial ResultsIRADIMED CORPORATION Announces First Quarter 2018 Financial Results
globenewswire.com - April 30 at 9:47 AM
IRadimed (IRMD) Set to Announce Earnings on MondayIRadimed (IRMD) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 23 at 9:20 AM
Analysts Anticipate Iradimed Corp (IRMD) to Announce $0.06 EPSAnalysts Anticipate Iradimed Corp (IRMD) to Announce $0.06 EPS
www.americanbankingnews.com - April 19 at 1:20 PM
IRADIMED CORPORATION to Hold 2018 First Quarter Financial Results Conference Call on April 30thIRADIMED CORPORATION to Hold 2018 First Quarter Financial Results Conference Call on April 30th
finance.yahoo.com - April 16 at 9:31 AM
Iradimed (IRMD) Stock Rating Lowered by Zacks Investment ResearchIradimed (IRMD) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:52 AM
Iradimed (IRMD) vs. Its Rivals Head-To-Head ReviewIradimed (IRMD) vs. Its Rivals Head-To-Head Review
www.americanbankingnews.com - April 9 at 5:10 PM
Iradimed (IRMD) Downgraded to "Hold" at Zacks Investment ResearchIradimed (IRMD) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 8 at 10:47 AM
Head to Head Review: Iradimed (IRMD) vs. Its CompetitorsHead to Head Review: Iradimed (IRMD) vs. Its Competitors
www.americanbankingnews.com - April 4 at 1:38 PM
Iradimed (IRMD) Now Covered by Analysts at Roth CapitalIradimed (IRMD) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - April 2 at 8:40 PM
Critical Survey: Iradimed (IRMD) vs. Its PeersCritical Survey: Iradimed (IRMD) vs. Its Peers
www.americanbankingnews.com - April 2 at 11:06 AM
Edited Transcript of IRMD earnings conference call or presentation 6-Feb-18 4:00pm GMTEdited Transcript of IRMD earnings conference call or presentation 6-Feb-18 4:00pm GMT
finance.yahoo.com - April 1 at 9:46 AM
 Iradimed Corp (IRMD) Given Consensus Recommendation of "Strong Buy" by Brokerages Iradimed Corp (IRMD) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 31 at 3:20 PM
Iradimed (IRMD) versus The Competition Financial AnalysisIradimed (IRMD) versus The Competition Financial Analysis
www.americanbankingnews.com - March 26 at 3:04 AM
Iradimed (IRMD) Upgraded to "Buy" by Zacks Investment ResearchIradimed (IRMD) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 25 at 10:57 AM
Iradimed Corp (IRMD) CEO Acquires $13,850.00 in StockIradimed Corp (IRMD) CEO Acquires $13,850.00 in Stock
www.americanbankingnews.com - March 20 at 8:32 PM
Iradimed Corp (IRMD) Insider Louis S. Waldman Sells 30,000 SharesIradimed Corp (IRMD) Insider Louis S. Waldman Sells 30,000 Shares
www.americanbankingnews.com - March 19 at 10:10 PM
IRADIMED CORPORATION to Present at 30th Annual Roth ConferenceIRADIMED CORPORATION to Present at 30th Annual Roth Conference
finance.yahoo.com - March 5 at 9:53 AM
 Analysts Set $18.00 Target Price for Iradimed Corp (IRMD) Analysts Set $18.00 Target Price for Iradimed Corp (IRMD)
www.americanbankingnews.com - February 21 at 5:18 PM
Iradimed (IRMD) Releases FY18 Earnings GuidanceIradimed (IRMD) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 6 at 9:42 AM
Iradimed (IRMD) Issues Q1 Earnings GuidanceIradimed (IRMD) Issues Q1 Earnings Guidance
www.americanbankingnews.com - February 6 at 9:24 AM
IRADIMED CORPORATION Announces Fourth Quarter 2017 Financial ResultsIRADIMED CORPORATION Announces Fourth Quarter 2017 Financial Results
finance.yahoo.com - February 6 at 9:02 AM
Iradimed (IRMD) Issues  Earnings Results, Beats Expectations By $0.08 EPSIradimed (IRMD) Issues Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - February 6 at 8:50 AM
Zacks: Analysts Set $14.00 Price Target for Iradimed Corp (IRMD)Zacks: Analysts Set $14.00 Price Target for Iradimed Corp (IRMD)
www.americanbankingnews.com - February 3 at 1:34 PM
Iradimed (IRMD) Downgraded to Hold at Zacks Investment ResearchIradimed (IRMD) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - February 3 at 11:12 AM
Iradimed (IRMD) Scheduled to Post Quarterly Earnings on TuesdayIradimed (IRMD) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 5:26 AM
Iradimed (IRMD) Upgraded by Zacks Investment Research to BuyIradimed (IRMD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 27 at 5:30 PM
Iradimed Corp. (IRMD) FY18 Guides Tops ViewsIradimed Corp. (IRMD) FY18 Guides Tops Views
www.streetinsider.com - January 24 at 9:27 AM
 Iradimed Corp (IRMD) Given $16.00 Consensus Target Price by Analysts Iradimed Corp (IRMD) Given $16.00 Consensus Target Price by Analysts
www.americanbankingnews.com - January 17 at 12:04 PM
Zacks: Analysts Set $16.00 Target Price for Iradimed Corp (IRMD)Zacks: Analysts Set $16.00 Target Price for Iradimed Corp (IRMD)
www.americanbankingnews.com - January 13 at 5:06 PM
Analysts Expect Iradimed Corp (IRMD) to Post $0.06 Earnings Per ShareAnalysts Expect Iradimed Corp (IRMD) to Post $0.06 Earnings Per Share
www.americanbankingnews.com - December 29 at 5:28 AM
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
finance.yahoo.com - December 27 at 1:27 PM
ETFs with exposure to IRadimed Corp. : December 26, 2017ETFs with exposure to IRadimed Corp. : December 26, 2017
finance.yahoo.com - December 26 at 3:10 PM
IRadimed Corp. :IRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017IRadimed Corp. :IRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:13 PM
 Analysts Expect Iradimed Corp (IRMD) Will Post Earnings of $0.06 Per Share Analysts Expect Iradimed Corp (IRMD) Will Post Earnings of $0.06 Per Share
www.americanbankingnews.com - December 24 at 3:26 PM
Zacks Investment Research Downgrades Iradimed (IRMD) to HoldZacks Investment Research Downgrades Iradimed (IRMD) to Hold
www.americanbankingnews.com - December 21 at 12:12 AM

SEC Filings

IRadimed (NASDAQ:IRMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IRadimed (NASDAQ:IRMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IRadimed (NASDAQ IRMD) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.